News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Enveric Biosciences
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
May 15, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
May 14, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
CSE:MBIO
ENVB
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
May 08, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
March 26, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
March 19, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
March 12, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
February 29, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
February 23, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
February 21, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
January 03, 2024
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
December 29, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
December 28, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
December 27, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
December 20, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
December 05, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
November 29, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
November 27, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
November 24, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences to Present at the Centurion One 5th Global Summit
October 20, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
October 18, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
October 11, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
October 03, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
September 27, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 20, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 18, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 11, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
September 05, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
August 30, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
August 21, 2023
From
Enveric Biosciences
Via
Business Wire
Tickers
ENVB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.